-
EC approves Fortescue Pharmaceuticals Symkevi in conjunction with Kalydeco for treatment of cystic fibrosis patients aged 12 and over
Time of Update: 2020-06-11
recently, the of the European Commission (EC) has approved Symkevi (tezacaftor/ivacaftor) in conjunction with Kalydeco (ivacaftor) for patients aged 12 and over with cystic fibrosis (CF) in additi
-
Alexion's main drug, Eculizumab, has been successful in clinical trials in Phase III
Time of Update: 2020-06-11
Alexion announced the success of its main drug (Phase III Clinical Trial (PREVENT) on the Phase III Clinical Disease (NMOSD) , Eculizumab has been approved by the United States and the European
-
FDA approves Roche's avetin ® combined chemotherapy (caplatinum and yewalcohol) for treatment of patients with advanced ovarian cancer
Time of Update: 2020-06-11
recently, the Swiss Roche Group announced that the U.S FDA (approved an avetin ® (bevazumab) combined chemotherapy (caplatinum and yew alcohol) for the treatment of patients with advanced (III or
-
FDA approves KALYDECO (ivacaftor) for use in infants with cystic fibrosis 12-24 months
Time of Update: 2020-06-11
recently, Vertex Pharmaceuticals announced that the U.S Food and Drug ( FDA ( ) approved KALYDECO (ivacaftor) for use in infants with cystic fibrosis (CF) 12-24 months of age children based o
-
Sun Pharma launches new anti-inflammatory drug Ilumya in the U.S. for treatment of adult patients with moderate to severe plaque psoriasis
Time of Update: 2020-06-11
recently, Indian drugmaker Sun Pharma announced the launch of the anti-inflammatory new drug (tildrakizumab-asmn, 100mg/mL) in the United States for the treatment of adults with moderate to sever
-
Metastatic colorectal cancer treatment drug furanitini capsule (Aiut) approved for market launch
Time of Update: 2020-06-11
today (September 5), the National Drug (Supervisory Authority announced that it has approved the treatment of metastatic colorectal cancer drug (eaut) for previous chemotherapy for fluorouretics
-
Inhalation therapy Yupeli gets the latest positive data in clinical Phase 3 trials
Time of Update: 2020-06-11
COPD, a serious disease with an increasing incidence, is the third leading cause of death in the United States, with nearly 15.7 million confirmed cases, or 6.4 percent of the population yesterday
-
FDA approves quasi-tyrosine kinase inhibitor LENVIMA for first-line treatment of non-recyctoctable hepatocellular carcinoma
Time of Update: 2020-06-11
liver cancer is the second leading cause of cancer-related death in the world, with statistics in 2012 showing that around 75,000 people die each year and 78,000 new confirmed cases each year recent
-
FDA approves sun pharma Xelpros for open-angle glaucoma or hyper-eye pressure patients
Time of Update: 2020-06-11
open-angle glaucoma (also primary or chronic glaucoma) is the most common type of glaucoma, accounting for more than 90% of glaucoma cases The disease is caused by blockages in the drainage tube in
-
Pfizer and Lilly reach all three trials on the painkiller tanezumab
Time of Update: 2020-06-11
today, Pfizer and Lilly jointly announced that they had reached the end of all three trials in the three-stage trial for pain management of osteoarthritis (OA) about Tanezumab Tanezumab is a hum
-
FDA approves Poteligeo for use in treatment of MF or SS adult patients
Time of Update: 2020-06-11
non-Hodgkin lymphoma is a cancer caused by lymphocytic cancer MF and SS are non-Hodgkin's lymphoma types of cancerous lymphocytes that affect the skin today, FDA (announced the approval of Potamul
-
FDA accepts re-application for new drug listing of DUOBRII washes for local treatment of plaque psoriasis
Time of Update: 2020-06-11
recently, , a of Bausch Health, a dermatological prescription drug company, reported that the U.S FDA (which has accepted the DUOBRII detergent (octanobuttabuterate and his zarodin, also known as
-
FDA approves new drug application for anti-cancer drug Xtandi
Time of Update: 2020-06-11
recently Pfizer and partner Astellas jointly announced that the U.S Food Drug ( FDA () has approved a supplementtoe new drug (application, expanding its current indications to include non-metas
-
FDA accepts clinical trial application for new drug RK-01 for diabetes
Time of Update: 2020-06-11
type 2 diabetes is a global epidemic, mostly after the age of 35-40, accounting for more than 90 percent of people with diabetes, affecting more than 400 million people worldwide days ago, ARKAYThe
-
Opdivo combines Yervoy (ipilimumab) first-line treatment for high-risk advanced renal cell carcinoma to be approved by Taiwan
Time of Update: 2020-06-11
Recently, Japanese drugmaker Ono Pharmaceutical series (OPTW) has received the of Taiwan's Taiwan ese food drug (T FDA (t. Chinese : Odivo, generic name: Navuriu monoantigen, nivolumab) suppl
-
FDA grants Galafold (migalastat) 123mg hard capsule accelerated approval
Time of Update: 2020-06-11
recently, Amicus Therapeutics announced that the U.S Food and Drug ( FDA ) has granted Galafold (migalastat) 123mg of accelerated approval for hard capsules Galafold is an oral, precision medi
-
Spark hemophilia gene therapy SPK-8011 remission rate of 97%
Time of Update: 2020-06-11
haemophilia A is a hereditary blood clotting disease that can cause uncontrolled bleeding In the United States, about 20,000 people are diagnosed with haemophilia A, and there are 320,000 haemophili
-
Novartis Entresto tablets achieve superior clinical benefits in PIONEER-HF trials
Time of Update: 2020-06-11
heart failure (heart failure) is a serious carry-on heart disease that causes weakness due to the inability of the heart to fully fill and drain blood recently, Novartis announced its Entresto tabl
-
FDA approves Roche Rituxan for treatment of adult patients with moderate to severe normal herpes
Time of Update: 2020-06-11
herpes is a group of autoimmune diseases caused by autoantibodies produced by B cells in the immune system that attack the proteins that connect between skin epidermal cells recently, the U.S FDA
-
FDA approves GW's Epidiolex oral liquid to market
Time of Update: 2020-06-11
Today, the U.S fda announced the approval of the Pharmaceutical ," the company's , to market Epidiolex is primarily used to treat two rare and severe types of epilepsy - Dravet syndrome and Len
